中华内分泌外科杂志
中華內分泌外科雜誌
중화내분비외과잡지
CHINESE JOURNAL OF ENDOCRINE SURGERY
2009年
6期
370-373
,共4页
乳腺癌%凝血纤溶
乳腺癌%凝血纖溶
유선암%응혈섬용
Breast tumor%Coagulation-fibrinolysis
目的 研究乳腺癌凝血纤溶异常与其转移、激素受体状态、分期等生物学行为的密切关系.方法 检测30例乳腺癌血浆6项凝血和纤溶指标,统计分析其变化与淋巴结转移、细胞增殖、受体状态等的关系.结果 良性对照组与乳腺癌组FiB由(3.05±0.44)g/L增高至(3.39±0.52)g/L(P＜0.05)、D-Di由(0.27±0.06)μg/ml增高至(0.36±0.16)μg/ml(P＜0.05)、PAI-1由(26.14±3.30)ng/ml增高至(34.59±3.68)ng/ml(P＜0.01),差异均有统计学意义.腋窝淋巴结转移阳性者的血浆FiB(3.70±0.47)g/L和PAI-1(37.36±2.71)ng/ml较无转移者增多(P＜0.05);细胞增殖抗原Ki67表达≥30%者PAI-1含量增加(36.40±3.57)ng/ml(P＜0.05).t-PA含量在不同激素受体状态下的差别有统计学意义(P＜0.05).不同TNM病理分期乳腺癌患者之间APTT(P＜0.01)、FiB(P＜0.01)、D-Di(P＜0.05)和PAI(P＜0.05)差异有统计学意义.结论 凝血纤溶指标与乳腺癌增殖、转移、分期等生物学行为有密切关系,可作为判断预后和术后复发转移的监测指标,并有利于血栓前状态的判断.
目的 研究乳腺癌凝血纖溶異常與其轉移、激素受體狀態、分期等生物學行為的密切關繫.方法 檢測30例乳腺癌血漿6項凝血和纖溶指標,統計分析其變化與淋巴結轉移、細胞增殖、受體狀態等的關繫.結果 良性對照組與乳腺癌組FiB由(3.05±0.44)g/L增高至(3.39±0.52)g/L(P＜0.05)、D-Di由(0.27±0.06)μg/ml增高至(0.36±0.16)μg/ml(P＜0.05)、PAI-1由(26.14±3.30)ng/ml增高至(34.59±3.68)ng/ml(P＜0.01),差異均有統計學意義.腋窩淋巴結轉移暘性者的血漿FiB(3.70±0.47)g/L和PAI-1(37.36±2.71)ng/ml較無轉移者增多(P＜0.05);細胞增殖抗原Ki67錶達≥30%者PAI-1含量增加(36.40±3.57)ng/ml(P＜0.05).t-PA含量在不同激素受體狀態下的差彆有統計學意義(P＜0.05).不同TNM病理分期乳腺癌患者之間APTT(P＜0.01)、FiB(P＜0.01)、D-Di(P＜0.05)和PAI(P＜0.05)差異有統計學意義.結論 凝血纖溶指標與乳腺癌增殖、轉移、分期等生物學行為有密切關繫,可作為判斷預後和術後複髮轉移的鑑測指標,併有利于血栓前狀態的判斷.
목적 연구유선암응혈섬용이상여기전이、격소수체상태、분기등생물학행위적밀절관계.방법 검측30례유선암혈장6항응혈화섬용지표,통계분석기변화여림파결전이、세포증식、수체상태등적관계.결과 량성대조조여유선암조FiB유(3.05±0.44)g/L증고지(3.39±0.52)g/L(P＜0.05)、D-Di유(0.27±0.06)μg/ml증고지(0.36±0.16)μg/ml(P＜0.05)、PAI-1유(26.14±3.30)ng/ml증고지(34.59±3.68)ng/ml(P＜0.01),차이균유통계학의의.액와림파결전이양성자적혈장FiB(3.70±0.47)g/L화PAI-1(37.36±2.71)ng/ml교무전이자증다(P＜0.05);세포증식항원Ki67표체≥30%자PAI-1함량증가(36.40±3.57)ng/ml(P＜0.05).t-PA함량재불동격소수체상태하적차별유통계학의의(P＜0.05).불동TNM병리분기유선암환자지간APTT(P＜0.01)、FiB(P＜0.01)、D-Di(P＜0.05)화PAI(P＜0.05)차이유통계학의의.결론 응혈섬용지표여유선암증식、전이、분기등생물학행위유밀절관계,가작위판단예후화술후복발전이적감측지표,병유리우혈전전상태적판단.
Objective To study the relation between coagulation-fibrinolysis and metastasis, hormone receptor and TNM stage of breast cancer. Methods The plasm levels of six coagulation-fibrinolysis indexes of 30 breast cancer patients were tested, which included activated partial thromboplastin time(APTT), fibrinogen(FIB), D-dimer(D-Di), tissue type plasminogen activator (t-PA)and plasminogen activator inhibitor-1(PAI-1). Statistic analysis of the relation between the changes of these indexes and metastasis, hormone receptor and breast cancer cell proliferation was performed. Results There were statistically significant differences between the malignant and benign breast disease in FiB(3.05±0.44)g/L vs(3.39±0.52)g/L(P＜0.05),D-Di(0.27±0.06)μg/ml vs(0.36±0.16)μg/ml(P＜0.05) and PAI-1(26.14±3.30)ng/ml vs(34.59±3.68)ng/ml (P＜0.01). The levels of plasma FIB (3.70±0.47)g/L and PAI-1 (37.36±2.71)ng/ml in metastasis group were higher than those in the non-metastasis group (P＜0.01). Significantly higher levels of PAI-1(36.40±3.57)ng/ml(P＜0.05)in expression of Ki67≥30% in the patients with lymph node involvement were seen. Conclusion Coagulation-fibrinolysis indexes were related to the proliferation, invasion, metastasis and clinical stage of breast cancer and it can serve as an important marker for predicting breast cancer's biological behavior and prognosis.
